BridgeBio Pharma (BBIO) is up 15.7% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely drivers are a combination of fresh clinical data for acoramidis and a large new financing package that appears to strengthen BridgeBio’s launch runway. This could also reflect investor optimism around the company’s broader rare-disease pipeline and the commercial traction already shown by Attruby.
Details:
BridgeBio disclosed an agreement for up to $1 billion in newly issued convertible preferred equity with investors including Sixth Street and HealthCare Royalty, giving the company added funding for current and planned launches.The company said the financing comes as Attruby continues to expand and as BridgeBio prepares for three additional potential U.S. product launches over the next 12 months.BridgeBio also announced new analyses showing acoramidis was associated with early and sustained kidney-protective effects in ATTR-CM, including improved chronic kidney function trends through Month 30.Earlier company updates highlighted strong first-quarter 2026 revenue, led by Attruby, which may have reinforced the market’s view that BridgeBio now has both commercial momentum and a better-funded balance sheet.Sources:
SEC, BridgeBio Pharma, GlobeNewswire
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 85 times in the past 6 months. Of those trades, 0 have been purchases and 85 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 66 sales selling 454,156 shares for an estimated $32,490,210.
- JENNIFER E. COOK has made 0 purchases and 4 sales selling 129,603 shares for an estimated $8,764,426.
- ANDREA ELLIS sold 64,921 shares for an estimated $4,211,301
- RANDAL W. SCOTT has made 0 purchases and 7 sales selling 20,000 shares for an estimated $1,426,012.
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 2 sales selling 13,600 shares for an estimated $1,016,147.
- HANNAH VALANTINE has made 0 purchases and 3 sales selling 13,675 shares for an estimated $965,835.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,510 shares for an estimated $181,058.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive BBIO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$BBIO Hedge Fund Activity
We have seen 224 institutional investors add shares of $BBIO stock to their portfolio, and 172 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BROOKLANDS FUND MANAGEMENT LTD removed 2,750,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $204,215,000
- VIKING GLOBAL INVESTORS LP removed 2,551,500 shares (-17.7%) from their portfolio in Q1 2026, for an estimated $189,474,390
- CITADEL ADVISORS LLC added 2,475,758 shares (+354.6%) to their portfolio in Q1 2026, for an estimated $183,849,789
- JANE STREET GROUP, LLC added 1,415,877 shares (+414.2%) to their portfolio in Q1 2026, for an estimated $105,143,026
- POLAR CAPITAL HOLDINGS PLC added 1,219,960 shares (+93.9%) to their portfolio in Q1 2026, for an estimated $90,594,229
- TWO SIGMA INVESTMENTS, LP added 1,173,584 shares (+60.3%) to their portfolio in Q1 2026, for an estimated $87,150,347
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,170,996 shares (-60.5%) from their portfolio in Q1 2026, for an estimated $86,958,162
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 03/10/2026
- Barclays issued a "Overweight" rating on 01/28/2026
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 12 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.
Here are some recent targets:
- Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
- Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
- Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
- Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
- Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
- Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
BridgeBio Pharma Jumps as Investors React to Fresh Acoramidis Data and New Capital
BridgeBio Pharma (BBIO) is up 15.7% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely drivers are a combination of fresh clinical data for acoramidis and a large new financing package that appears to strengthen BridgeBio’s launch runway. This could also reflect investor optimism around the company’s broader rare-disease pipeline and the commercial traction already shown by Attruby.
Details:
Sources:
SEC, BridgeBio Pharma, GlobeNewswire
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 85 times in the past 6 months. Of those trades, 0 have been purchases and 85 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BBIO Hedge Fund Activity
We have seen 224 institutional investors add shares of $BBIO stock to their portfolio, and 172 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 12 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »